Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome.

Magnano L, Martínez A, Carreras J, Martínez-Trillos A, Giné E, Rovira J, Dlouhy I, Baumann T, Balagué O, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2017 Apr;58(4):842-850. doi: 10.1080/10428194.2016.1217525. Epub 2016 Aug 11.

PMID:
27687692
2.

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>.

Alonso-Álvarez S, Vidriales MB, Caballero MD, Blanco O, Puig N, Martin A, Peñarrubia MJ, Zato E, Galende J, Bárez A, Alcoceba M, Orfão A, González M, García-Sanz R.

Leuk Lymphoma. 2017 May;58(5):1144-1152. doi: 10.1080/10428194.2016.1239263. Epub 2016 Oct 12.

PMID:
27733075
3.

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

Wahlin BE, Sander B, Christensson B, Kimby E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97.

4.

Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.

Alvaro T, Lejeune M, Salvadó MT, Lopez C, Jaén J, Bosch R, Pons LE.

J Clin Oncol. 2006 Dec 1;24(34):5350-7.

PMID:
17135637
5.

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.

PMID:
27341313
6.

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.

Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM.

Blood Cancer J. 2015 Feb 20;5:e281. doi: 10.1038/bcj.2015.1.

7.

Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells.

Camacho FI, Bellas C, Corbacho C, Caleo A, Arranz-Sáez R, Cannata J, Menárguez J, Sánchez-Verde L, González-Camacho L, Pérez-Martín ME, Martínez-González MA, Alvaro T, Mollejo M, Ruíz-Marcellán C, Montalbán C, Piris MA.

Mod Pathol. 2011 May;24(5):698-707. doi: 10.1038/modpathol.2010.237. Epub 2011 Jan 14.

8.

[Clinical Significance of Detecting CD4+ T Cells in Peripheral Blood of Patients with Follicular lymphoma].

Liu W, Zhagn GX, Shi WZ, Dong L, Liu H, Shen XL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):449-454. doi: 10.7534/j.issn.1009-2137.2017.02.025. Chinese.

PMID:
28446291
9.

Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.

Yuan J, Greiner TC, Fu K, Smith LM, Aoun P, Chan WC, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Weisenburger DD.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):488-497.e2. doi: 10.1016/j.clml.2017.06.006. Epub 2017 Jun 16.

PMID:
28842137
10.

Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.

Moroch J, Copie-Bergman C, de Leval L, Plonquet A, Martin-Garcia N, Delfau-Larue MH, Molinier-Frenkel V, Belhadj K, Haioun C, Audouin J, Swerdlow SH, Marafioti T, Gaulard P.

Am J Surg Pathol. 2012 Nov;36(11):1636-46. doi: 10.1097/PAS.0b013e318268d9ff.

PMID:
23073322
11.

T-cell levels are prognostic in mantle cell lymphoma.

Nygren L, Wasik AM, Baumgartner-Wennerholm S, Jeppsson-Ahlberg Å, Klimkowska M, Andersson P, Buhrkuhl D, Christensson B, Kimby E, Wahlin BE, Sander B.

Clin Cancer Res. 2014 Dec 1;20(23):6096-104. doi: 10.1158/1078-0432.CCR-14-0889. Epub 2014 Oct 7.

12.

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E.

Clin Cancer Res. 2011 Jun 15;17(12):4136-44. doi: 10.1158/1078-0432.CCR-11-0264. Epub 2011 Apr 25.

13.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.

Maeng CH, Ahn SW, Ryu SY, Han S, Ko YH, Ji JH, Kim WS, Kim SJ.

Korean J Intern Med. 2016 May;31(3):560-9. doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.

14.

gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.

Braza MS, Caraux A, Rousset T, Lafaye de Micheaux S, Sicard H, Squiban P, Costes V, Klein B, Rossi JF.

J Immunol. 2010 Jan 1;184(1):134-40. doi: 10.4049/jimmunol.0901980. Epub 2009 Nov 30.

15.

Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.

Procházka V, Papajík T, Faber E, Raida L, Kapitáňová Z, Langová K, Prouzová Z, Jarošová M, Indrák K.

Leuk Lymphoma. 2014 Jul;55(7):1584-90. doi: 10.3109/10428194.2013.850167. Epub 2014 Feb 4.

PMID:
24180329
16.

Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma.

Zhang XY, Xu J, Zhu HY, Wang Y, Wang L, Fan L, Wu YJ, Li JY, Xu W.

Cancer Sci. 2016 Oct;107(10):1471-1476. doi: 10.1111/cas.13020. Epub 2016 Sep 14.

17.

Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma.

Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, Fukunaga A, Yanagita S, Nishikori M, Takaori-Kondo A, Arima N.

Int J Hematol. 2014 Jun;99(6):737-42. doi: 10.1007/s12185-014-1576-0. Epub 2014 Apr 23.

PMID:
24756873
18.

Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.

Plancarte F, López-Guillermo A, Arenillas L, Montoto S, Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E.

Eur J Haematol. 2006 Jan;76(1):58-63.

PMID:
16343272
19.

Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.

Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, Pogliani EM, Pioltelli PE.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.

PMID:
25468321
20.

Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.

Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, Bernd HW, Determann O, Hansmann ML, Möller P, Feller A, Stein H, Wacker HH, Dreyling M, Unterhalt M, Hiddemann W, Ott G; German Low Grade Lymphoma Study Group.

J Clin Oncol. 2007 Aug 1;25(22):3330-6.

PMID:
17664481

Supplemental Content

Support Center